Claus Garbe
Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
Bochem J, Weide B, Pawelec G, Garbe C, Meier F, Terheyden P, Uslu U, Wagner N, Eigentler T, Soffel D, Spreuer J, Amaral T, Zelba H, Wistuba-Hamprecht K. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. PloS one 2019; 14:e0221301.
16.08.2019Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
16.08.2019PloS one 2019; 14:e0221301
Bochem Jonas, Weide Benjamin, Pawelec Graham, Garbe Claus, Meier Friedegund, Terheyden Patrick, Uslu Ugur, Wagner Nikolaus, Eigentler Thomas, Soffel Daniel, Spreuer Janine, Amaral Teresa, Zelba Henning, Wistuba-Hamprecht Kilian
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
Wagner N, Forschner A, Leiter U, Garbe C, Eigentler T. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. Br J Cancer 2018; 119:339-346.
28.06.2018S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
28.06.2018Br J Cancer 2018; 119:339-346
Wagner Nikolaus, Forschner Andrea, Leiter Ulrike, Garbe Claus, Eigentler Thomas K
Safety of shortened infusion times for combined ipilimumab and nivolumab
Gassenmaier M, Garbe C, Eigentler T, Doecker D, Mueller A, Kofler L, Wagner N, Scheu A, Lipp H, Forschner A. Safety of shortened infusion times for combined ipilimumab and nivolumab. Cancer Immunol Immunother 2017; 67:135-140.
07.10.2017Safety of shortened infusion times for combined ipilimumab and nivolumab
07.10.2017Cancer Immunol Immunother 2017; 67:135-140
Gassenmaier Maximilian, Garbe Claus, Eigentler Thomas Kurt, Doecker Dennis, Mueller Alisa, Kofler Lukas, Wagner Nikolaus, Scheu Alexander, Lipp Hans-Peter, Forschner Andrea
Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma
Wagner N, Utikal J, Enk A, Umansky V, Garbe C, Naeher H, Holland-Letz T, Busch C, Ikenberg K, Eubel J, Herpel E, Pflugfelder A, Lichtenberger R, Kehrel C, Tarnanidis K, Reith M, Weide B, Gebhardt C. Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. Int J Cancer 2015; 137:2607-17.
14.07.2015Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma
14.07.2015Int J Cancer 2015; 137:2607-17
Wagner Nikolaus, Utikal Jochen, Enk Alexander, Umansky Viktor, Garbe Claus, Naeher Helmut, Holland-Letz Tim, Busch Christian, Ikenberg Kristian, Eubel Jana, Herpel Esther, Pflugfelder Annette, Lichtenberger Ramtin, Kehrel Coretta, Tarnanidis Kathrin, Reith Maike, Weide Benjamin, Gebhardt Christoffer
Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma
Mehra T, Naumann A, Clasen S, Dummer R, Claussen C, Röcken M, Moos R, Guenova E, Mann S, Grözinger G, Garbe C. Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma. PloS one 2014; 9:e112535.
10.11.2014Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma
10.11.2014PloS one 2014; 9:e112535
Mehra Tarun, Naumann Aline, Clasen Stephan, Dummer Reinhard, Claussen Claus Detlef, Röcken Martin, Moos Rudolf, Guenova Emmanuella, Mann Steven, Grözinger Gerd, Garbe Claus
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Voskens C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Klein C, Keller U, Goldinger S, Loquai C, Robert C, Kaehler K, Berking C, Bergmann T, Bockmeyer C, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Heinzerling L. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PloS one 2013; 8:e53745.
14.01.2013The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
14.01.2013PloS one 2013; 8:e53745
Voskens Caroline J, Mateus Christine, Mohr Peter, Paetzold Sylvie, Satzger Imke, Schadendorf Dirk, Schlaeppi Marc, Schuler Gerold, Schuler-Thurner Beatrice, Trefzer Uwe, Ulrich Jens, Vaubel Julia, von Moos Roger, Weder Patrik, Wilhelm Tabea, Göppner Daniela, Dummer Reinhard, Klein Christina, Keller Ullrich, Goldinger Simone M, Loquai Carmen, Robert Caroline, Kaehler Katharina C, Berking Carola, Bergmann Tanja, Bockmeyer Clemens L, Eigentler Thomas, Fluck Michael, Garbe Claus, Gutzmer Ralf, Grabbe Stephan, Hauschild Axel, Hein Rüdiger, Hundorfean Gheorghe, Justich Armin, Heinzerling Lucie M
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients
Meier F, Garbe C, Knaudt B, Zielinski C, Leiter U, Forschner A, Eigentler T, Clasen S, Guenova E, Berneburg M. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. J Am Acad Dermatol 2009; 60:863-8.
01.05.2009Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients
01.05.2009J Am Acad Dermatol 2009; 60:863-8
Meier Friedegund, Garbe Claus, Knaudt Björn, Zielinski Christina, Leiter Ulrike, Forschner Andrea, Eigentler Thomas, Clasen Stephan, Guenova Emmanuella, Berneburg Mark